EX-2.1 2 dex21.htm MASTER JOINT VENTURE AGREEMENT MASTER JOINT VENTURE AGREEMENT by and between Maxygen, Inc., a Delaware Corporation, Astellas Phama Inc., a Japanese Corporation, and Astellas Bio Inc., a Delaware Corporation Dated as of June 30, 2009...Master Joint Venture Agreement • May 5th, 2020 • Delaware
Contract Type FiledMay 5th, 2020 JurisdictionThis Master Joint Venture Agreement (this “Agreement”) is made and entered into as of this 30th day of June, 2009 by and between Maxygen, Inc. a Delaware corporation, having its principal offices at 515 Galveston Drive Redwood City, CA 94063 (together with its Affiliates, “Maxygen”), Astellas Pharma Inc., a Japanese corporation, having its principal offices at 2-3-11, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan (“Astellas”) and Astellas Bio Inc., a Delaware corporation, having its principal offices at Three Parkway North Deerfield, IL 60015-2548 (“Bio”). Maxygen, Astellas and Bio are together referred to herein as the “Parties.”
MASTER JOINT VENTURE AGREEMENT by and between Maxygen, Inc., a Delaware Corporation, Astellas Phama Inc., a Japanese Corporation, and Astellas Bio Inc., a Delaware Corporation Dated as of June 30, 2009Master Joint Venture Agreement • July 1st, 2009 • Maxygen Inc • Services-commercial physical & biological research • Delaware
Contract Type FiledJuly 1st, 2009 Company Industry JurisdictionThis Master Joint Venture Agreement (this “Agreement”) is made and entered into as of this 30th day of June, 2009 by and between Maxygen, Inc. a Delaware corporation, having its principal offices at 515 Galveston Drive Redwood City, CA 94063 (together with its Affiliates, “Maxygen”), Astellas Pharma Inc., a Japanese corporation, having its principal offices at 2-3-11, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan (“Astellas”) and Astellas Bio Inc., a Delaware corporation, having its principal offices at Three Parkway North Deerfield, IL 60015-2548 (“Bio”). Maxygen, Astellas and Bio are together referred to herein as the “Parties.”